LCTX Insider Trading Activity and SEC Form 4 Filings
LCTX insider trading summary
Over the past 12 months, insiders at Lineage Cell Therapeutics, Inc. (LCTX) reported 1 open-market purchase worth $24K by 1 insider and no sales on SEC Form 4. Net insider buying was $24K.
Latest LCTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 12, 2026 | Brian M Culley | President and CEO | Buy | $24K (15,000 @ $1.63) |
| Jan 27, 2025 | Broadwood Partners, L.P. | Director | Buy | $6.0M (7,894,737 @ $0.76) |
| Jan 27, 2025 | Broadwood Partners, L.P. | Director | Buy | $0 (0 @ $0.00) |
| Jan 27, 2025 | Broadwood Capital Inc | 10% Owner | Buy | $0 (0 @ $0.00) |
| Jan 27, 2025 | Neal C Bradsher | Director | Buy | $0 (0 @ $0.00) |
| Jan 27, 2025 | Neal C Bradsher | Director | Buy | $6.0M (7,894,737 @ $0.76) |
| Jan 27, 2025 | Broadwood Capital Inc | 10% Owner | Buy | $6.0M (7,894,737 @ $0.76) |
| Nov 26, 2024 | Jill Ann Howe | Chief Financial Officer | Buy | $9K (15,000 @ $0.59) |
| Nov 26, 2024 | George A. Samuel III | General Counsel | Buy | $9K (15,000 @ $0.60) |
| Nov 22, 2024 | Michael H. Mulroy | Insider | Buy | $23K (40,000 @ $0.57) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.